Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Alvin Luk"'
Autor:
Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Wei Li, Yang Zhang, Jifeng Feng, Jianmin Yang, Huilai Zhang, Chuan Jin, Yu Yang, Jianda Hu, Zhao Wang, Zhengming Jin, Hang Su, Huaqing Wang, Haiyan Yang, Weijun Fu, Mingzhi Zhang, Xiaohong Zhang, Yun Chen, Xiaoyan Ke, Li Liu, Ding Yu, Guo’an Chen, Xiuli Wang, Jie Jin, Tao Sun, Xin Du, Ying Cheng, Pingyong Yi, Xielan Zhao, Chaoming Ma, Jiancheng Cheng, Katherine Chai, Alvin Luk, Eugene Liu, Xin Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-5 (2020)
Abstract Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise approach to demonstrate biosimi
Externí odkaz:
https://doaj.org/article/9fa40c795d7040e7acb499b265963df7
Autor:
Jiajia Yuan, Jiaxun Zhao, Chong Ye, Long Pang, Xin Zhang, Alvin Luk, Yangyang Du, Kai Yoon Fan, Xiaowen Zhang, Bin Li, Changzheng Chen
Publikováno v:
BioMed Research International. 2023:1-14
Background. LHON is a progressive disease with early disease onset and male predominance, usually causing devastating visual loss to patients. These systematic review and meta-analysis are aimed at summarizing epidemiology, disease onset and progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc4d267d5cc8f7a90dcfed4c09d21e77
https://doi.org/10.1155/2023/1107866
https://doi.org/10.1155/2023/1107866
Autor:
Alvin Luk, Yongfu Wang, Xiaoxia Zuo, Scott Liu, Xiaofeng Zeng, Baozeng Zhao, Rui Liu, Lan He, Cibo Huang, Weidong Jiang, Pei Hu, Xin Lu, Katherine Chai, Xinjun Guo, Xiao Zhang, Eugene Liu, Zhuoli Zhang, Zhenyu Jiang, Wenting Qiu, Jian Xu, Xin Zhang, Xiumei Liu, Xia Chen
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background Biologic products, such as rituximab and adalimumab, have revolutionized the treatment for chronic inflammatory disorders, providing an option to patients who were non-responsive to conventional systemic therapies. In China, rituximab is o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28e24844c97259cd209bafb7ea1fd6e2
https://doi.org/10.1136/annrheumdis-2019-eular.3669
https://doi.org/10.1136/annrheumdis-2019-eular.3669
Autor:
Xin Zhang, Alvin Luk, Jixun Sun, Yanhua Ding, Yiwen Han, Katherine Chai, Weidong Jiang, He Gao, Xinjun Guo, Min Wu, Eugene Liu, Guiling Chen, Tianli Zhang, Scott Liu
Publikováno v:
Poster Presentations.
Background Adalimumab first launched in China in August 2010 with now more than 10 million people have its indications.1, 2 However, the relative high cost of the biologic drug limits the treatment accessibility and reduces the quality of life in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6a21e1488635e86f6b4e94eb485ee0a
https://doi.org/10.1136/annrheumdis-2019-eular.1909
https://doi.org/10.1136/annrheumdis-2019-eular.1909
Autor:
Johannes C.M. Van der Loo, Jerome M. Teitel, Benjamin J. Samelson-Jones, Adam Cuker, Xavier M. Anguela, Marcus E. Carr, Catherine E. McGuinn, Yifeng Chen, Linda B. Couto, Adam Giermasz, Suvankar Majumdar, Katie Wachtel, Jonathan M. Ducore, Stefan Tiefenbacher, Margaret V. Ragni, J. Fraser Wright, Olga Zelenaia, Katherine A. High, Yun Liu, John E.J. Rasko, Daniel Takefman, Lisa M. Sullivan, Angela Winters, Daniel Hui, Alvin Luk, Spencer K. Sullivan, Valder R. Arruda, Lindsey A. George
Publikováno v:
The New England journal of medicine. 377(23)
The prevention of bleeding with adequately sustained levels of clotting factor, after a single therapeutic intervention and without the need for further medical intervention, represents an important goal in the treatment of hemophilia.We infused a si
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbb2657407ff2d3c3546fcc638e6677
https://pubmed.ncbi.nlm.nih.gov/29274719
https://pubmed.ncbi.nlm.nih.gov/29274719
Autor:
Johnny, Mahlangu, Jerry S, Powell, Margaret V, Ragni, Pratima, Chowdary, Neil C, Josephson, Ingrid, Pabinger, Hideji, Hanabusa, Naresh, Gupta, Roshni, Kulkarni, Patrick, Fogarty, David, Perry, Amy, Shapiro, K John, Pasi, Shashikant, Apte, Ivan, Nestorov, Haiyan, Jiang, Shuanglian, Li, Srividya, Neelakantan, Lynda M, Cristiano, Jaya, Goyal, Jurg M, Sommer, Jennifer A, Dumont, Nigel, Dodd, Karen, Nugent, Gloria, Vigliani, Alvin, Luk, Aoife, Brennan, Glenn F, Pierce, Michael, Guerrera
Publikováno v:
Blood. 123:317-325
This phase 3 pivotal study evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ad06452fa42ce883fe6419d169422e
https://doi.org/10.1182/blood-2013-10-529974
https://doi.org/10.1182/blood-2013-10-529974
Autor:
Yongping Song, Pei Hu, Katherine Chai, Xiaonan Hong, Dong Wang, Xiaohong Han, Xiaofeng Zeng, Kevin Li, Weidong Jiang, Kaka Y. Hong, Yan Qin, Shuiyu Zhao, Alvin Luk, Xin Zhang, Chaoming Ma, Qingyuan Zhang, Scott Liu, Peng Ting, Dan Yao, Yuankai Shi, Eugene Liu, Jiancheng Cheng
Publikováno v:
Blood. 134:2878-2878
Background In February 2019, the National Medicinal Products Administration (NMPA) approved the first China-manufactured rituximab (RTX) biosimilar, HLX01, for the treatment of non-Hodgkin's lymphoma in accordance to the development of biosimilar gui
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe97a0a002e12bf410f91ea10310734e
https://doi.org/10.1182/blood-2019-130603
https://doi.org/10.1182/blood-2019-130603
Autor:
Haiyan Jiang, Justin McCue, Jennifer A. Dumont, Margaret V. Ragni, Alvin Luk, Glenn F. Pierce, Jaya Goyal, Doris Quon, Ella Li, Neil C. Josephson, Gregory Cheng, Jurg M. Sommer, Xin Zhang, Jerry S. Powell, Margaret Barbetti, Li Lian
Publikováno v:
Blood. 119:3031-3037
Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57dd629f7f276f7d9d066499d6eaec47
https://doi.org/10.1182/blood-2011-09-382846
https://doi.org/10.1182/blood-2011-09-382846
Autor:
Xiaomei Jin, Glenn F. Pierce, Jennifer A. Dumont, Robert T. Peters, Alan J. Bitonti, Alvin Luk
Publikováno v:
Therapeutic Proteins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fcf6341c59a3ed736cc84b64fe02ed79
https://doi.org/10.1002/9783527644827.ch10
https://doi.org/10.1002/9783527644827.ch10
Autor:
Shashikant Apte, Margaret V. Ragni, Alvin Luk, Kathelijne Peerlinck, Lynda M. Cristiano, Alison Innes, Xuefeng Wang, Karen Nugent, Haiyan Jiang, John Pasi, Glenn F. Pierce, Cedric Hermans, David Perry, Shannon Jackson, Shuanglian Li, Hervé Chambost, Jerry S. Powell, Neil C. Josephson, Margareth C. Ozelo, G. Allen, Brian Robinson, Johnny Mahlangu, Aoife Brennan
Publikováno v:
British journal of haematology. 168(1)
In the phase 3 B-LONG (Recombinant Factor IX Fc Fusion Protein [rFIXFc] in Subjects With Haemophilia B) study, rFIXFc demonstrated a prolonged half-life compared with recombinant factor IX (rFIX), and safety and efficacy for prophylaxis and treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e0e2a4db20a3aa81182e86ff837b5e8
https://pubmed.ncbi.nlm.nih.gov/25208598
https://pubmed.ncbi.nlm.nih.gov/25208598